Evidence map›Paper›PMID 38201455›Full record

ArticleCancers2023

Expression and Localization of Ferritin-Heavy Chain Predicts Recurrence for Breast Cancer Patients with a

Shuoying Qu, A Mieke Timmermans, Bernadette A M Heemskerk-Gerritsen, Anita M A C Trapman-Jansen, Renée Broeren-Foekens, Wendy J C Prager-van der Smissen, Hoesna El Hassnaoui, Tim van Tienhoven, Claudia K Bes-Stobbe, Pieter J Westenend and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Shuoying QuDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
A Mieke TimmermansDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Bernadette A M Heemskerk-GerritsenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-9724-6693
Anita M A C Trapman-JansenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Renée Broeren-FoekensDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Wendy J C Prager-van der SmissenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Hoesna El HassnaouiDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Tim van TienhovenDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0009-0001-6431-7467
Claudia K Bes-StobbePathan BV, Kleiweg 500, 3045 PM Rotterdam, The Netherlands.
Pieter J WestenendLaboratory of Pathology, 3318 AL Dordrecht, The Netherlands.
Carolien H M van DeurzenDepartment of Pathology, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands.
John W M MartensDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0002-3428-3366
Maartje J HooningDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0001-6763-0857
Antoinette HollestelleDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.ORCID 0000-0003-1166-1966
Erasmus MC · NLPathoFinder (Netherlands) · NL

Funding

Dutch Cancer Society DDHK 2004-3124
6 · The paper itself

Abstract

The ferritin-heavy chain (FTH1) is the catalytic subunit of the ferroxidase ferritin, which prevents oxidative DNA damage via intracellular iron storage. FTH1 was shown to be a prognostic marker for triple-negative breast cancer (BC) patients and associated with an enrichment of CD8+ effector T cells. However, whether the expression and localization of FTH1 are also associated with clinical outcome in other BC subtypes is unknown. Here, we investigated the association of FTH1 with time to survival in BCs from 222

Indexed as

BRCA1BRCA2breast cancerFTH1germline mutationsurvivalT-cell response

Identifiers

PMID38201455
PMCPMC10778040
OpenAlexW4390006401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.